MRNAModerna, Inc.

Nasdaq modernatx.com


$ 79.49 $ 0.23 (0.29 %)    

Wednesday, 11-Sep-2024 15:59:57 EDT
QQQ $ 468.28 $ 9.96 (2.17 %)
DIA $ 409.73 $ 1.01 (0.25 %)
SPY $ 554.79 $ 5.63 (1.03 %)
TLT $ 100.61 $ -0.08 (-0.08 %)
GLD $ 232.25 $ -0.37 (-0.16 %)
$ 79.51
$ 79.47 x 200
-- x --
-- - --
$ 62.55 - $ 170.47
3,370,687
na
30.56B
$ 0.34
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 02-23-2024 12-31-2023 10-K
4 11-03-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 02-24-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-03-2022 06-30-2022 10-Q
10 05-04-2022 03-31-2022 10-Q
11 02-25-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-26-2021 12-31-2020 10-K
16 10-30-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 02-27-2020 12-31-2019 10-K
20 11-06-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-13-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nasdaq-sp-500-set-for-modest-gains-as-investors-eye-august-inflation-data-and-ecb-rate-decision

U.S. stocks could open Thursday’s session modestly higher after the remarkable recovery they staged in the previous session. Th...

 gsk-halts-herpes-simplex-virus-vaccine-development-clears-path-for-other-contenders-like-moderna-biontech

GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clini...

Core News & Articles

Carisma retains all rights in autoimmune disease beyond the two nominated targets, which will be exclusively partnered with Mod...

 wall-street-rallies-after-last-weeks-sell-off-palantir-soars-on-sp-500-inclusion-airlines-rally-whats-driving-markets-monday

U.S. stocks started the new week with strong gains, as all major indices and sectors in the S&P 500 were in the green by mi...

 why-is-moderna-stock-trading-higher-on-monday

Moderna's Laval, Quebec, facility received a Drug Establishment License from Health Canada, allowing it to produce mRNA vac...

 modernas-quebec-facility-gains-health-canada-approval-set-to-produce-mrna-vaccines-domestically

Moderna, Inc. (NASDAQ:MRNA) today announced that its manufacturing facility in Laval, Quebec, has been granted a Drug Establish...

 intel-moderna-and-dollar-general-were-among-top-10-large-cap-losers-in-august-are-the-others-in-your-portfolio

10 worst performing large-cap stocks in August: Super Micro, Dollar General, Snap, PDD Holdings, Intel, Tencent Music, Gold Fie...

Core News & Articles

 - Reuters

Core News & Articles

https://www.nbcnews.com/health/health-news/us-prepares-possible-arrival-severe-strain-mpox-rcna169926 Senior Biden administrati...

 modernas-investigational-mpox-vaccine-more-effective-than-current-approved-shot-animal-study-shows

Moderna is conducting a Phase 1/2 trial of mRNA-1769, a potential mpox vaccine for adults. Early research shows it may outperfo...

Core News & Articles

https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4523 Today, close to 100,000 mpox vaccine doses will arrive in the ...

 jim-cramer-oklo-is-losing-money-hand-over-fist-but-this-private-equity-stock-is-a-buy

The "Mad Money" host said Oklo Inc. is a company that is again losing so much money "I can't even look at it."

 modernas-updated-covid-19-vaccine-targeting-sars-cov-2-variant-jn1-receives-authorization-recommendation-from-ema-committee

- Reuters 

 moderna-reports-encouraging-results-on-its-mpox-vaccine-as-outbreaks-in-africa-spread---stat-news

https://www.statnews.com/2024/09/04/moderna-mpox-vaccine-study-results/

 uk-taiwan-approve-modernas-updated-covid-19-shot

The Medicines and Healthcare Products Regulatory Agency has approved Moderna's updated COVID-19 vaccine targeting the JN.1 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION